A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy

Conclusion: FA-PTX-EB showed prolonged blood circulation, enhanced drug accumulation in tumors, higher therapeutic index, and lower side effects than either free PTX or monofunctional FA-PTX and EB-PTX. The results support the potential of using EB for the development of long-acting therapeutics.

Source: Theranostics - June 20, 2018 Category: Molecular Biology Authors: Lingling Shan, Xin Zhuo, Fuwu Zhang, Yunlu Dai, Guizhi Zhu, Bryant C. Yung, Wenpei Fan, Kefeng Zhai, Orit Jacobson, Dale O. Kiesewetter, Ying Ma, Guizhen Gao, Xiaoyuan Chen Tags: Research Paper Source Type: research